Abstract

The success of the Colorado ACTU in performing studies of antiretroviral therapy depends on the close support of a basic virology laboratory. The Virology Core Laboratory of the Colorado ACTU has fulfilled this purpose since establishment of our subunit in August, 1990 and is certified by the ACTG Virology Committee in the performance of HIV-1 cultures and serum p24 antigen assays. A proposal is therefore submitted to provide virology core laboratory support to the Colorado ACTU Clinical Core and to other cooperating ACTU's as outlined in the RFA. In addition to serum p24 antigen determinations and qualitative HIV-1 culture, our laboratory can perform plasma viremia assays, quantitative HIV-1 microcultures, zidovudine resistance assays, and amplification of HIV-1 DNA by polymerase chain reaction for genotype analysis of RT. Additional techniques for quantifying viral load and assaying antiretroviral drug susceptibility are being developed or will be adopted as they become available.

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project--Cooperative Agreements (U01)
Project #
5U01AI032770-02
Application #
3769641
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
2
Fiscal Year
1993
Total Cost
Indirect Cost

  Institution

Name
University of Colorado Denver
Department
Type
DUNS #
065391526
City
Aurora
State
CO
Country
United States
Zip Code
80045

  Publications

Winham, Stacey J; Slater, Andrew J; Motsinger-Reif, Alison A (2010) A comparison of internal validation techniques for multifactor dimensionality reduction. BMC Bioinformatics 11:394
Williams, Pl; Wu, Jw; Cohn, Se et al. (2009) Improvement in lipid profiles over 6 years of follow-up in adults with AIDS and immune reconstitution. HIV Med 10:290-301
Skowron, Gail; Spritzler, John G; Weidler, Jodi et al. (2009) Replication capacity in relation to immunologic and virologic outcomes in HIV-1-infected treatment-naive subjects. J Acquir Immune Defic Syndr 50:250-8
Gerber, John G; Kitch, Douglas W; Fichtenbaum, Carl J et al. (2008) Fish oil and fenofibrate for the treatment of hypertriglyceridemia in HIV-infected subjects on antiretroviral therapy: results of ACTG A5186. J Acquir Immune Defic Syndr 47:459-66
Sattler, Fred R; Rajicic, Natasa; Mulligan, Kathleen et al. (2008) Evaluation of high-protein supplementation in weight-stable HIV-positive subjects with a history of weight loss: a randomized, double-blind, multicenter trial. Am J Clin Nutr 88:1313-21
Ma, Qing; Forrest, Alan; Rosenkranz, Susan L et al. (2008) Pharmacokinetic interaction between efavirenz and dual protease inhibitors in healthy volunteers. Biopharm Drug Dispos 29:91-101
Okusanya, Olanrewaju; Forrest, Alan; DiFrancesco, Robin et al. (2007) Compartmental pharmacokinetic analysis of oral amprenavir with secondary peaks. Antimicrob Agents Chemother 51:1822-6
Mulligan, Kathleen; Zackin, Robert; Von Roenn, Jamie H et al. (2007) Testosterone supplementation of megestrol therapy does not enhance lean tissue accrual in men with human immunodeficiency virus-associated weight loss: a randomized, double-blind, placebo-controlled, multicenter trial. J Clin Endocrinol Metab 92:563-70
Bosch, Ronald J; Bennett, Kara; Collier, Ann C et al. (2007) Pretreatment factors associated with 3-year (144-week) virologic and immunologic responses to potent antiretroviral therapy. J Acquir Immune Defic Syndr 44:268-77
Rosenkranz, Susan L; Yarasheski, Kevin E; Para, Michael F et al. (2007) Antiretroviral Drug Levels and Interactions Affect Lipid, Lipoprotein, and Glucose Metabolism in HIV-1 Seronegative Subjects: A Pharmacokinetic-Pharmacodynamic Analysis. Metab Syndr Relat Disord 5:163-73

Showing the most recent 10 out of 55 publications